COVID player and Pfizer-partnered Valneva eyes $100M Nasdaq IPO

French biotech Valneva, which has developed a lineup of traveler vaccines and is starting a late-stage COVID vax effort, is seeking to level up to the Nasdaq with a $100 million IPO.